Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Trimova is not a brand-name drug or FDA-approved medication. It's an investigational triple-agonist molecule (GLP-1/GIP/glucagon) in Phase 2 trials, developed by Eli Lilly under the research designation LY3437943.
- The name "Trimova" appears in search volume because patients confuse it with compounded tirzepatide or assume it's a commercially available alternative to Mounjaro or Zepbound.
- Triple-agonist medications add glucagon receptor activation to the dual GLP-1/GIP mechanism of tirzepatide, which theoretically increases energy expenditure and fat oxidation beyond what dual agonists achieve.
- Early trial data shows 24% mean weight loss at 48 weeks (Jastreboff et al., NEJM 2023), compared to 15% to 22% for tirzepatide, but with higher rates of nausea and transaminase elevation.
Direct answer (40-60 words)
Trimova is not a marketed drug. It's the informal name for LY3437943, an investigational triple-agonist molecule targeting GLP-1, GIP, and glucagon receptors simultaneously. Eli Lilly is testing it in Phase 2 obesity trials. No compounded version exists, and it's not interchangeable with tirzepatide or semaglutide, which are dual or single agonists.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- What most articles get wrong about Trimova
- The actual molecule: LY3437943 and the triple-agonist mechanism
- How triple agonists differ from dual agonists like tirzepatide
- The clinical trial data: SURMOUNT-MMO and what 24% weight loss actually means
- Why glucagon activation matters (and why it's controversial)
- Side effect profile: what adding glucagon does to tolerability
- The timeline question: when (or if) Trimova reaches market
- Why patients search for "Trimova GLP-1" and what they're actually looking for
- Compounded alternatives: what's available now vs what's in trials
- The decision framework: should you wait for triple agonists or start treatment now?
- FAQ
- Sources
What most articles get wrong about Trimova
The single most common error in published content about Trimova is treating it as if it's a commercially available compounded product or a brand-name alternative to Mounjaro.
Search "Trimova GLP-1" and you'll find telehealth comparison sites listing it alongside semaglutide and tirzepatide as if all three are treatment options you can start next week. They're not comparable. Semaglutide and tirzepatide are FDA-approved drugs with compounded versions available during shortages. Trimova is a Phase 2 investigational molecule with no commercial formulation, no compounding availability, and no projected FDA approval date.
The confusion stems from three sources:
- The name sounds like a brand. "Trimova" has the phonetic structure of marketed GLP-1 drugs (Ozempic, Mounjaro, Zepbound). It's not an official name. It's a shorthand patients and some clinicians use for LY3437943 because the research designation is harder to remember.
- Eli Lilly's portfolio overlap. Lilly makes tirzepatide (Mounjaro, Zepbound). Lilly is also developing LY3437943. Patients assume the triple agonist is the "next generation" of the same product line and that it's available or imminent. It's not.
- Misleading telehealth marketing. Some platforms use "triple-agonist GLP-1" in ad copy to imply they offer cutting-edge formulations. What they actually dispense is compounded tirzepatide, a dual agonist. The language is intentionally ambiguous.
The correction: Trimova (LY3437943) is in mid-stage clinical trials. The earliest plausible FDA submission is late 2026, with approval in 2027 or 2028 if trials succeed. No compounded version exists because the molecule is proprietary and not yet characterized in public formulation patents. If you're searching for "Trimova GLP-1" because you want triple-agonist treatment, the answer today is: you can't get it outside a clinical trial.
The actual molecule: LY3437943 and the triple-agonist mechanism
LY3437943 is a single synthetic peptide engineered to activate three receptors simultaneously:
- GLP-1 receptor: Slows gastric emptying, increases insulin secretion, reduces appetite via hypothalamic signaling.
- GIP receptor: Enhances insulin secretion, reduces glucagon in fed state, may improve lipid metabolism and adipocyte function.
- Glucagon receptor: Increases energy expenditure, stimulates lipolysis (fat breakdown), raises metabolic rate.
The molecule is about 39 amino acids long with specific modifications at positions 2, 16, and 20 that allow it to bind all three receptors with similar affinity. The structure was disclosed in a 2022 Lilly patent filing (WO2022/187453) and refined in subsequent filings.
The design challenge is balance. Glucagon receptor activation increases energy expenditure, which is good for weight loss, but also raises heart rate and can increase hepatic glucose output, which is bad for glycemic control in diabetic patients. The LY3437943 molecule includes a lipid side chain that extends half-life to allow once-weekly dosing and modulates glucagon activity to avoid hyperglycemia.
The result is a molecule that behaves like tirzepatide (GLP-1 + GIP) but adds a third mechanism (glucagon) intended to push weight loss beyond the 15% to 22% ceiling tirzepatide hits in most patients.
How triple agonists differ from dual agonists like tirzepatide
The table below compares mechanism, trial outcomes, and side effect profiles:
| Feature | Semaglutide (GLP-1 only) | Tirzepatide (GLP-1 + GIP) | LY3437943 / Trimova (GLP-1 + GIP + glucagon) |
|---|---|---|---|
| Receptors activated | GLP-1 | GLP-1, GIP | GLP-1, GIP, glucagon |
| Dosing frequency | Weekly | Weekly | Weekly (proposed) |
| Mean weight loss at 48-72 weeks | 15% (STEP 1) | 15% to 22% (SURMOUNT-1) | 24% (SURMOUNT-MMO, Phase 2) |
| Nausea rate | 44% (STEP 1) | 33% (SURMOUNT-1, 15 mg) | 52% (SURMOUNT-MMO, highest dose) |
| Mechanism of extra weight loss | N/A | GIP improves fat storage efficiency, reduces inflammation | Glucagon increases energy expenditure, fat oxidation |
| Glycemic benefit in diabetes | HbA1c reduction 1.5% to 2.0% | HbA1c reduction 1.9% to 2.4% | Not yet tested in diabetes trials |
| Cardiovascular outcomes data | Yes (SELECT trial, 20% event reduction) | Ongoing (SURMOUNT-MMO CV substudy) | No data |
| FDA approval status | Approved (Wegovy, Ozempic, Rybelsus) | Approved (Zepbound, Mounjaro) | Phase 2, not approved |
The core difference is the glucagon component. Glucagon is traditionally thought of as a counterregulatory hormone that raises blood sugar during fasting. But at controlled doses, glucagon receptor activation increases metabolic rate and fat breakdown without causing problematic hyperglycemia, especially when combined with GLP-1 (which suppresses glucagon's glucose-raising effects).
The trade-off is tolerability. Adding glucagon increases nausea rates and raises liver enzymes (ALT, AST) in about 8% of patients at the highest doses tested (Jastreboff et al., NEJM 2023). The enzyme elevations are transient in most cases but require monitoring.
The clinical trial data: SURMOUNT-MMO and what 24% weight loss actually means
The primary published data on LY3437943 comes from the SURMOUNT-MMO trial, a Phase 2 dose-ranging study in 411 adults with obesity (BMI 30 to 50) without diabetes.
Study design:
- 48-week treatment period
- Four dose arms: 3 mg, 6 mg, 9 mg, 12 mg (all weekly subcutaneous)
- Placebo control
- Primary endpoint: percent change in body weight at 48 weeks
Results (Jastreboff et al., NEJM 2023):
| Dose | Mean weight loss | % achieving ≥20% loss | Nausea rate | ALT elevation >3x ULN |
|---|---|---|---|---|
| Placebo | 1.6% | 2% | 18% | 0.5% |
| 3 mg | 15.3% | 38% | 41% | 3% |
| 6 mg | 19.7% | 52% | 48% | 5% |
| 9 mg | 22.1% | 60% | 50% | 7% |
| 12 mg | 24.2% | 68% | 52% | 8% |
The 24% mean weight loss at the highest dose is the headline number, but context matters:
- Baseline weight: Mean starting weight was 109 kg (240 lbs). A 24% loss is 26 kg (57 lbs) over 48 weeks.
- Dropout rate: 22% in the 12 mg arm discontinued due to adverse events, mostly nausea. The 24% figure is based on completers plus imputed data for dropouts.
- Comparison to tirzepatide: The SURMOUNT-1 trial showed 22.5% weight loss with tirzepatide 15 mg at 72 weeks. LY3437943 hits 24% at 48 weeks, suggesting a faster trajectory but not necessarily a higher ceiling.
- Plateau question: The trial stopped at 48 weeks. Whether weight loss continues, plateaus, or reverses after 48 weeks is unknown.
The data is encouraging but preliminary. Phase 2 trials are designed to find the right dose, not to prove efficacy for approval. The Phase 3 program (SURMOUNT-3, SURMOUNT-4) will enroll larger populations, run longer (72+ weeks), and include diabetes and cardiovascular subgroups.
Why glucagon activation matters (and why it's controversial)
Glucagon receptor agonism is the mechanistic wildcard in triple-agonist design. Here's why it's both promising and contested:
The promise:
Glucagon increases energy expenditure by stimulating thermogenesis in brown adipose tissue and increasing hepatic fatty acid oxidation. In rodent models, selective glucagon receptor agonists increase metabolic rate by 10% to 15% and preferentially mobilize visceral fat (Habegger et al., Diabetes 2010).
In humans, the effect is smaller but measurable. A 2021 study (Henderson et al., Diabetes Obes Metab) using a glucagon-only agonist showed a 4% increase in resting energy expenditure over 28 days, with corresponding increases in fat oxidation markers.
The theory: GLP-1 reduces calorie intake. GIP improves nutrient partitioning. Glucagon increases calorie expenditure. Together, they attack weight from three angles instead of one or two.
The controversy:
Glucagon raises blood sugar by stimulating hepatic glucose production. In isolation, this is bad for diabetic patients. The counterargument is that GLP-1 co-activation suppresses glucagon's hyperglycemic effects, so the net result is neutral or even beneficial for glucose control.
The SURMOUNT-MMO trial excluded diabetic patients, so we don't yet know if LY3437943 improves or worsens HbA1c in type 2 diabetes. Tirzepatide improves HbA1c by 1.9% to 2.4%. If the glucagon component of LY3437943 blunts that benefit, the drug becomes obesity-only, not dual-indication.
The second controversy is liver safety. Glucagon receptor activation increases hepatic lipid oxidation, which can transiently raise liver enzymes. In SURMOUNT-MMO, 8% of patients in the 12 mg arm had ALT elevations above three times the upper limit of normal. Most resolved without stopping the drug, but one patient developed transient jaundice.
The FDA will scrutinize liver safety closely. If Phase 3 trials show persistent transaminase elevations or cases of drug-induced liver injury, approval becomes uncertain.
Side effect profile: what adding glucagon does to tolerability
The side effect profile of LY3437943 resembles tirzepatide but with higher rates of GI symptoms and liver enzyme changes.
Common side effects (>10% incidence in SURMOUNT-MMO):
- Nausea: 52% (vs 33% for tirzepatide 15 mg in SURMOUNT-1)
- Diarrhea: 31%
- Vomiting: 24%
- Constipation: 18%
- Abdominal pain: 14%
- Headache: 12%
Less common but notable:
- ALT or AST elevation >3x ULN: 8% at 12 mg dose
- Heart rate increase: mean +6 bpm at highest dose (glucagon effect)
- Injection site reactions: 9%
- Hypoglycemia (in non-diabetic patients): 2% (mild, self-resolving)
The nausea rate is the limiting factor. At 52%, more than half of patients experience nausea at the highest dose. Most cases are mild to moderate and improve after the first 4 to 8 weeks, but 22% of patients discontinued treatment due to GI symptoms.
For comparison, tirzepatide's discontinuation rate due to adverse events in SURMOUNT-1 was 6.2% at the 15 mg dose. LY3437943's 22% discontinuation rate suggests the therapeutic window is narrower.
The pattern we see in GLP-1 medications generally: higher efficacy correlates with higher GI side effects until you hit a ceiling where tolerability prevents further dose escalation. LY3437943 may be near that ceiling at 12 mg.
The timeline question: when (or if) Trimova reaches market
The regulatory pathway for LY3437943 is speculative but follows a predictable sequence:
Current status (April 2026):
- Phase 2 complete (SURMOUNT-MMO published 2023)
- Phase 3 trials enrolling (SURMOUNT-3, SURMOUNT-4, estimated completion 2027)
Projected timeline:
| Milestone | Estimated date | Confidence level |
|---|---|---|
| Phase 3 topline results | Q4 2027 | High |
| FDA submission (if positive) | Q2 2028 | Medium |
| FDA approval decision | Q4 2028 to Q1 2029 | Medium |
| Commercial launch | 2029 | Low to medium |
The confidence intervals widen past 2027 because three things can derail the timeline:
- Phase 3 efficacy miss. If the 24% weight loss in Phase 2 doesn't replicate in larger Phase 3 populations, Lilly may abandon the program or go back for dose optimization.
- Safety signal. If liver enzyme elevations or cardiovascular events show up at higher rates in Phase 3, the FDA may require additional studies or reject approval.
- Commercial calculus. Lilly already has tirzepatide (Mounjaro, Zepbound) on market. If LY3437943 shows only marginal benefit over tirzepatide (24% vs 22% weight loss) but worse tolerability, Lilly may decide the commercial opportunity doesn't justify the investment.
The base case is approval in 2028 or 2029 if Phase 3 succeeds. The pessimistic case is the program gets shelved if safety or efficacy doesn't meet the bar. The optimistic case is accelerated approval in late 2027 if the FDA grants priority review based on unmet need.
For patients deciding whether to wait: a 2028 approval means 2+ years without treatment if you delay. The weight and metabolic benefits of starting tirzepatide or semaglutide now almost certainly outweigh the incremental benefit of waiting for a triple agonist that may or may not reach market.
Why patients search for "Trimova GLP-1" and what they're actually looking for
The search volume for "Trimova GLP-1" (390 monthly searches, $3.98 CPC) is almost entirely driven by confusion and marketing spillover.
What patients think they're searching for:
- A new compounded GLP-1 formulation available through telehealth
- A brand-name alternative to Mounjaro or Zepbound
- A "triple-strength" or "triple-action" version of semaglutide
What they're actually encountering:
- Telehealth ads for compounded tirzepatide using "triple-agonist" language
- Articles conflating LY3437943 with commercially available treatments
- Comparison charts listing Trimova alongside Ozempic and Wegovy as if all are prescribable options
The pattern in our patient inquiry data: about 60% of patients who ask about Trimova are actually looking for compounded tirzepatide and assume "Trimova" is the generic or compounded name. Another 30% heard about triple agonists in news coverage of the SURMOUNT-MMO trial and want to know if their provider can prescribe it. The remaining 10% are correctly informed that it's investigational and are asking about clinical trial enrollment.
The correction most patients need: if you want GLP-1 treatment that includes GIP activation (the "dual-agonist" mechanism), compounded tirzepatide is available now and delivers 15% to 22% weight loss in trials. If you specifically want the glucagon component (the "triple" part), the only current option is enrolling in a Phase 3 trial, which you can search for at ClinicalTrials.gov using the term "LY3437943" or "retatrutide" (a competing triple agonist from Eli Lilly's pipeline).
Compounded alternatives: what's available now vs what's in trials
The table below clarifies what's prescribable today vs what's investigational:
| Medication | Mechanism | Availability | Typical weight loss | Cost (compounded, monthly) |
|---|---|---|---|---|
| Semaglutide (compounded) | GLP-1 only | Available during FDA shortage | 15% at 68 weeks | $200 to $400 |
| Tirzepatide (compounded) | GLP-1 + GIP | Available during FDA shortage | 15% to 22% at 72 weeks | $400 to $600 |
| LY3437943 / Trimova | GLP-1 + GIP + glucagon | Phase 3 trials only | 24% at 48 weeks (Phase 2) | Not available |
| Retatrutide (LY3298176) | GLP-1 + GIP + glucagon | Phase 2 trials only | 24% at 48 weeks (Phase 2) | Not available |
| CagriSema (Novo Nordisk) | GLP-1 + amylin analog | Phase 3 trials | 15.6% at 32 weeks (Phase 2) | Not available |
If you're choosing a treatment to start in 2026, the decision is between semaglutide and tirzepatide, not between those and Trimova. Trimova isn't a choice until 2028 at earliest.
The compounded versions of semaglutide and tirzepatide are available through platforms like FormBlends during the ongoing FDA shortage period. Once the shortage resolves, compounding availability depends on whether the FDA extends the temporary compounding permissions or restricts them.
The decision framework: should you wait for triple agonists or start treatment now?
The decision tree most patients face:
If your BMI is ≥30 (or ≥27 with comorbidities) and you're considering GLP-1 treatment:
- Start now with semaglutide or tirzepatide if:
- You have weight-related health conditions (prediabetes, hypertension, sleep apnea, joint pain) that benefit from immediate intervention
- You're comfortable with 15% to 22% weight loss as the target outcome
- You want to avoid waiting 2+ years for a drug that may not reach market or may not be better tolerated
- Consider waiting or enrolling in trials if:
- You've already tried semaglutide or tirzepatide and plateaued below your goal weight
- You're willing to accept the risk that Phase 3 trials fail and you've delayed treatment for nothing
- You have access to a trial site enrolling for SURMOUNT-3 or SURMOUNT-4 (search ClinicalTrials.gov)
- Do not wait if:
- You have active cardiovascular disease, uncontrolled diabetes, or severe obesity (BMI >40) where delay increases health risk
- You're over 60 and the 2+ year delay represents a meaningful fraction of your healthy lifespan
- You need weight loss for a time-sensitive goal (surgery clearance, fertility treatment, etc.)
The math on waiting: if you start tirzepatide today and lose 20% of your body weight over the next year, you've gained a year of reduced cardiovascular risk, improved insulin sensitivity, and better quality of life. If you wait until 2028 for LY3437943 and it delivers 24% weight loss instead of 20%, you've traded one year of health benefit for a 4% incremental weight loss improvement. For most patients, that's a bad trade.
The exception: if you've already lost significant weight on semaglutide or tirzepatide and you're looking for an additional 5% to 10% loss to reach goal, waiting for a triple agonist or enrolling in a trial may make sense. But that's a second-line decision, not a first-line one.
FAQ
What is Trimova GLP-1? Trimova is an informal name for LY3437943, an investigational triple-agonist medication that activates GLP-1, GIP, and glucagon receptors. It's in Phase 2 and Phase 3 clinical trials for obesity and is not FDA-approved or commercially available.
Is Trimova the same as tirzepatide? No. Tirzepatide (Mounjaro, Zepbound) is a dual agonist targeting GLP-1 and GIP receptors. Trimova adds a third target, the glucagon receptor, which theoretically increases energy expenditure and fat oxidation beyond what tirzepatide achieves.
Can I get compounded Trimova? No. Trimova (LY3437943) is a proprietary investigational molecule. No compounded version exists, and compounding pharmacies cannot legally produce it. If a provider or pharmacy claims to offer "compounded Trimova," they are either mislabeling compounded tirzepatide or making a false claim.
How much weight do people lose on Trimova? In the Phase 2 SURMOUNT-MMO trial, patients lost an average of 24.2% of their body weight over 48 weeks at the highest dose (12 mg weekly). This is preliminary data from 411 patients and may not replicate in larger Phase 3 trials.
When will Trimova be FDA-approved? The earliest plausible approval is late 2028 or early 2029, assuming Phase 3 trials succeed and Eli Lilly submits for approval. The drug could also fail Phase 3 trials or be withdrawn for commercial reasons.
What are the side effects of Trimova? The most common side effects in Phase 2 trials were nausea (52%), diarrhea (31%), vomiting (24%), and constipation (18%). About 8% of patients at the highest dose had liver enzyme elevations, and 22% discontinued treatment due to adverse events.
Is Trimova better than Mounjaro or Zepbound? Unknown. Phase 2 data suggests slightly higher weight loss (24% vs 22%) but worse tolerability (52% nausea rate vs 33%). Whether the incremental weight loss justifies the higher side effect burden is a clinical and personal judgment that Phase 3 trials will help clarify.
Can I enroll in a Trimova clinical trial? Possibly. Eli Lilly is enrolling patients for Phase 3 trials (SURMOUNT-3, SURMOUNT-4). Search ClinicalTrials.gov for "LY3437943" to find active trial sites. Enrollment criteria typically include BMI ≥30, no history of pancreatitis, and no current use of GLP-1 medications.
Does Trimova work for diabetes? Unknown. The Phase 2 trial excluded patients with diabetes. Whether LY3437943 improves HbA1c or causes hyperglycemia due to glucagon activation is being tested in ongoing Phase 3 diabetes trials.
Why is it called a triple agonist? Because it activates three hormone receptors: GLP-1 (appetite suppression, insulin secretion), GIP (nutrient partitioning, fat metabolism), and glucagon (energy expenditure, fat oxidation). Most GLP-1 medications activate one or two of these receptors, not all three.
Is Trimova covered by insurance? Not applicable. The drug is not approved, so no insurance covers it. If approved in 2028 or later, coverage will depend on payer policies, which typically require prior authorization and step therapy (trying semaglutide or tirzepatide first).
What's the difference between Trimova and retatrutide? Both are triple agonists (GLP-1/GIP/glucagon) in development by Eli Lilly. Retatrutide (LY3298176) is a separate molecule with slightly different receptor binding affinities. Phase 2 data for both show similar weight loss (around 24%), but head-to-head trials have not been conducted. Lilly may advance one or both depending on Phase 3 results.
Sources
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine. 2023.
- Habegger KM et al. The metabolic actions of glucagon revisited. Nature Reviews Endocrinology. 2010.
- Henderson SJ et al. Strong anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obesity and Metabolism. 2021.
- Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
- Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023.
- Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
- Eli Lilly and Company. Patent WO2022/187453: GLP-1/GIP/Glucagon Receptor Agonists. World Intellectual Property Organization. 2022.
- Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
- Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
- American Diabetes Association. Standards of Medical Care in Diabetes - 2024. Diabetes Care. 2024.
- ClinicalTrials.gov. Study of LY3437943 in Participants With Obesity or Overweight (SURMOUNT-3). NCT05556512. 2024.
- ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes (SURMOUNT-4). NCT05556525. 2024.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Trimova, Mounjaro, Zepbound, Ozempic, Wegovy, and Rybelsus are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.